409 related articles for article (PubMed ID: 32312419)
21. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
23. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
25. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
26. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
28. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
29. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
30. Cdks, cyclins and CKIs: roles beyond cell cycle regulation.
Lim S; Kaldis P
Development; 2013 Aug; 140(15):3079-93. PubMed ID: 23861057
[TBL] [Abstract][Full Text] [Related]
31. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
32. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
Iavarone A; Massagué J
Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429
[TBL] [Abstract][Full Text] [Related]
33. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
34. Novel plant-specific cyclin-dependent kinase inhibitors induced by biotic and abiotic stresses.
Peres A; Churchman ML; Hariharan S; Himanen K; Verkest A; Vandepoele K; Magyar Z; Hatzfeld Y; Van Der Schueren E; Beemster GT; Frankard V; Larkin JC; Inzé D; De Veylder L
J Biol Chem; 2007 Aug; 282(35):25588-96. PubMed ID: 17599908
[TBL] [Abstract][Full Text] [Related]
35. A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.
Asghar A; Chohan TA; Khurshid U; Saleem H; Mustafa MW; Khursheed A; Alafnan A; Batul R; Bin Break MK; Almansour K; Anwar S
Chem Biol Interact; 2024 Apr; 393():110940. PubMed ID: 38467339
[TBL] [Abstract][Full Text] [Related]
36. The Pho85 kinase, a member of the yeast cyclin-dependent kinase (Cdk) family, has a regulation mechanism different from Cdks functioning throughout the cell cycle.
Nishizawa M; Suzuki K; Fujino M; Oguchi T; Toh-e A
Genes Cells; 1999 Nov; 4(11):627-42. PubMed ID: 10620010
[TBL] [Abstract][Full Text] [Related]
37. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
38. The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
[TBL] [Abstract][Full Text] [Related]
39. Cell-cycle control and plant development.
Inagaki S; Umeda M
Int Rev Cell Mol Biol; 2011; 291():227-61. PubMed ID: 22017978
[TBL] [Abstract][Full Text] [Related]
40. Function of hybrid human-yeast cyclin-dependent kinases in Saccharomyces cerevisiae.
Bitter GA
Mol Gen Genet; 1998 Oct; 260(1):120-30. PubMed ID: 9829836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
